Cargando…

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Jessica, Patel, Manali, Gridelli, Cesare, de Marinis, Filippo, Waterkamp, Daniel, McCusker, Margaret E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391942/ https://www.ncbi.nlm.nih.gov/pubmed/28410405 http://dx.doi.org/10.1371/journal.pone.0175679

Ejemplares similares

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
por: Spagnuolo, Alessia, et al.
Publicado: (2023)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
por: Leleu, X, et al.
Publicado: (2017)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India
por: Gill, Naresh, et al.
Publicado: (2019)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India
por: Khan, Samsuddin, et al.
Publicado: (2014)

Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma
por: Laganà, M., et al.
Publicado: (2022)

Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT)
por: Normanno, Nicola, et al.
Publicado: (2020)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

A Review of Second- and Third-line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome
por: Costello, Michael F., et al.
Publicado: (2019)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
por: Ray-Coquard, I, et al.
Publicado: (2013)

Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review
por: Velickovic, Vladica M., et al.
Publicado: (2020)

Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer
por: Wang, Xiaolei, et al.
Publicado: (2022)

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer
por: Walker, Mark S, et al.
Publicado: (2012)

Second-line treatment for renal cell cancer
por: Di Lorenzo, G, et al.
Publicado: (2012)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe
por: Chimbetete, Cleophas, et al.
Publicado: (2018)

Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data
por: Hiroi, Shinzo, et al.
Publicado: (2016)

Everolimus is Safe as a Second-/Third-Line Therapy in Pediatric Autoimmune Hepatitis
por: Jannone, Giulia, et al.
Publicado: (2022)

Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma
por: Wang, Lining, et al.
Publicado: (2016)

Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017)

Cholangiocarcinoma: the quest for a second-line systemic treatment
por: Vienot, Angélique, et al.
Publicado: (2019)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
por: Gómez-Ulloa, David, et al.
Publicado: (2020)

Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
por: Choi, In Sil, et al.
Publicado: (2018)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Quantifying pediatric patient need for second- and third-line HIV treatment: A tool for decision-making in resource-limited settings
por: Mohammed, Perry, et al.
Publicado: (2019)

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
por: Gridelli, C., et al.
Publicado: (2021)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
por: Hua, Jie, et al.
Publicado: (2018)

Internal endoscopic drainage as first line or second line treatment in case of postsleeve gastrectomy fistulas
por: Gonzalez, J. M., et al.
Publicado: (2018)

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment
por: Nowaczyk, Alicja, et al.
Publicado: (2022)

Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
por: Celik, Alan, et al.
Publicado: (2023)

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
por: Cevik, Muge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btu08o4n5mjdqt2dr6m8rj9svi